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Abstract
Background: Cathepsin B and urokinase plasminogen activator receptor (uPAR) are both known to be overexpressed in
gliomas. Our previous work and that of others strongly suggest a relationship between the infiltrative phenotype of glioma
and the expression of cathepsin B and uPAR. Though their role in migration and adhesion are well studied the effect of
these molecules on cell cycle progression has not been thoroughly examined.
Methodology/Principal Findings: Cathespin B and uPAR single and bicistronic siRNA plasmids were used to downregulate
these molecules in SNB19 and U251 glioma cells. FACS analysis and BrdU incorporation assay demonstrated G0/G1 arrest
and decreased proliferation with the treatments, respectively. Immunoblot and immunocyto analysis demonstrated
increased expression of p27
Kip1 and its nuclear localization with the knockdown of cathepsin B and uPAR. These effects
could be mediated by aVb3/PI3K/AKT/FOXO pathway as observed by the decreased aVb3 expression, PI3K and AKT
phosphorylation accompanied by elevated FOXO3a levels. These results were further confirmed with the increased
expression of p27
Kip1 and FOXO3a when treated with Ly294002 (10 mM) and increased luciferase expression with the siRNA
and Ly294002 treatments when the FOXO binding promoter region of p27
Kip1 was used. Our treatment also reduced the
expression of cyclin D1, cyclin D2, p-Rb and cyclin E while the expression of Cdk2 was unaffected. Of note, the Cdk2-cyclin E
complex formation was reduced significantly.
Conclusion/Significance: Our study indicates that cathepsin B and uPAR knockdown induces G0/G1 arrest by modulating
the PI3K/AKT signaling pathway and further increases expression of p27
Kip1 accompanied by the binding of FOXO3a to its
promoter. Taken together, our findings provide molecular mechanism for the G0/G1 arrest induced by the downregulation
of cathepsin B and uPAR in SNB19 and U251 glioma cells.
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Introduction
Malignant glioma, a common tumor among the intracranial
tumors, remains formidable despite aggressive surgery, radiother-
apy and chemotherapy [1]. Cathepsin B and urokinase-type
plasminogen activator receptor (uPAR) are both known to be
overexpressed in gliomas and, as such, are attractive targets for
gene therapy. During cancer cell invasion, these proteins, either
individually or in combination, function to degrade the extracel-
lular matrix, thereby facilitating metastasis. Our previous work
and that of others strongly suggest a relationship between the
infiltrative phenotype of glioma and the expression of cathepsin B
and uPAR. Though their role in migration and adhesion are well
studied [2–4], the effect of these molecules on cell cycle
progression has not been thoroughly examined. Moreover,
disruption of cell cycle control is a hallmark of cancer [5,6]. In
particular, the reduced expression of p27
Kip1, which is a member
of the Kip family of cyclin-dependent kinase (Cdk) inhibitors, has
been extensively observed in human cancers, and its low levels are
often associated with a worse prognosis [7,8]. Increased suscep-
tibility to cancer and multi-organ hyperplasia have been reported
in p27
Kip1-null mice [9]. It plays a crucial role in the control of cell
proliferation by inhibiting the activities of complexes of G1 cyclins
and Cdks and, as such, is an important candidate for therapeutic
tumor suppression [10]. Some factors, including accelerated
proteolysis, sequestration by cyclin D-Cdk complexes, and
phosphorylation events that lead to nuclear export and/or
retention in the cytosol, have significant roles in inhibiting the
p27
Kip1 function in various cancers [11]. Cytoplasmic transloca-
tion of p27
Kip1 has been increasingly recognized in primary
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11668human tumors associated with poor survival whereas nuclear
expression confers a more favorable outcome [12].
Another hallmark of most cancers, including glioma, is the
increased activity of PI3K/AKT pathway that controls many
biological functions like cell proliferation, survival, and insulin
response [13]. Constitutive activation of this pathway facilitates
tumor formation both by supporting S-phase entry and by
conferring resistance to apoptotic signals that normally restrict
uncontrolled cell growth [14,15]. In the presence of growth
factors, AKT negatively regulates FOXO proteins by phosphor-
ylating them [16,17], which results in their binding to 14-3-3
proteins and is followed by their nuclear export [18]. FOXO
factors function as transcriptional activators and bind as
monomers to the consensus DNA sequence TTGTTTAC
[19,20]. Depending on the cell system studied, forced expression
or activation of FOXO factors triggers apoptotic responses or cell
cycle arrest [21]. Cell cycle inhibitory effect of FOXO factor
through increased transcription of p27
kip1 has been reported in
gliomas [22,23]. Several integrins play important roles in
promoting cell proliferation, migration and survival in vitro and
in vivo. Both uPAR and cathepsin B are known to be associated in
close proximity to aVb3 integrins and has been implicated in their
ability to initiate signaling events [24].
In an attempt to elucidate the roles of cathepsin B and uPAR in
cell cycle progression, we analyzed the activity of crucial regulators
of the G0/G1 transition including p27
Kip1 by downregulating
cathepsin B and uPAR both individually and simultaneously in
SNB19 and U251 glioma cells. Here, we show that shRNA-
mediated downregulation of cathepsin B and uPAR results in G0/
G1 arrest, prominent increased expression of p27
Kip1 and
inhibition of p-Rb. This increased expression of p27
Kip1 correlates
with decreased expression of p-PI3K, p-AKT, cyclin E, cyclin D1,
cyclin D2 and increased expression of FOXO3a protein. We also
show that increased expression of p27
Kip1 is due to the efficient
binding of FOXO3a on its promoter, which was analyzed by the
luciferase expression.
Results
Knockdown of cathepsin B and uPAR decreases cell
proliferation and induces G0/G1 arrest
To gain insight into the molecular roles of cathepsin B and
uPAR, we knocked down the expression of these molecules using
shRNA in SNB19 and U251 glioma cells and then analyzed the
effects on cell proliferation and cell cycle. After 36 hrs of
transfection, western blot analysis showed a 8063% and
8263% decrease in cathespin B expression in SNB19 and U251
cells, respectively when treated with pC (shRNA construct against
cathepsinB). Cells treated with pU (shRNA construct against
uPAR) did not show appreciable difference in cathespin B
expression when compared to controls (9862%). pCU-treated
(shRNA bicistronic construct against cathepsin B and uPAR) cells
showed 86–91% decreased expression of cathepsin B in both
SNB19 and U251 cells (p,0.01). Similarly, uPAR expression was
reduced by 75–80% in both cell lines when treated with pU. Cells
treated with pC did not show any difference in expression when
compared to controls (9563%). uPAR expression in pCU-treated
cells was significantly reduced by 80–91% (Fig. 1A) (p,0.01).
Immunoblot analysis for GAPDH expression revealed equal
loading. Cell proliferation analysis by BrdU incorporation assay
showed that the depletion of cathepsin B and uPAR individually
and simultaneously resulted in a significant reduction in the
proliferation rates by: 37–40% (pU), 34–36% (pC) and 67–68%
(pCU) in both cell lines (Fig. 1B). In contrast, untreated control
and SV (scrambled vector)-transfected cells showed 100%
proliferation in both cell lines. Similarly, MTT assay showed
decreased number of cells with the treatments (pU: 38–40%; pC:
33–35% and pCU: 65–68%) compared to the controls (98–100%)
in both the cell lines (Fig. S1A). Decreased growth suppression was
associated with cell cycle arrest. As shown in Figure 1C, cell cycle
analysis showed an increase in the G1 phase fraction with the
treatments (pU: 58.3462%, 66.6862%; pC: 56.8862%,
63.8462%; and pCU: 72.1661%, 78.4562% in SNB19 and
U251, respectively) and a concomitant decrease in the S phase
(pU: 15.2363%, 7.9863%; pC: 1662%, 8.5661%; and pCU:
8.1261%, 2.9562% in SNB19 and U251 cells, respectively) and
G2/M phase (pU: 26.4361%, 25.3461%; pC: 27.1261%,
27.662%; and pCU: 19.1261%, 18.662% in SNB19 and
U251 cells, respectively) fractions. Negligible number of cells were
present in sub G0/G1 phase, hence, the data is not included. Cell
cycle analysis of untreated control and SV-transfected cells of
SNB19 and U251 cells showed 4065% in G1 phase, 15610% in
S phase and 3265% in G2/M phase. These results demonstrate
that the decrease in cell proliferation is due to the block of
progression from G1 to S phase, and the effect was almost the
same in both the cell lines. However, cell cycle analysis at 48 hrs of
transfection showed significant increase (20–40%) in sub G0/G1
phase with the treatments compared to the controls (7–8%) and
concomitant decrease in the G0/G1, S and G2/M phases
indicating that the cells were entering into the apoptotic phase
(Fig. S1B).
Cathepsin B and uPAR depletion affects the p27
Kip1
expression and its subcellular localization
It is well known that p27
Kip1 plays an important role in G0/G1
arrest. Hence, we checked the expression of p27
Kip1 using RT-
PCR and western blot analysis. RT-PCR and immunoblot analysis
of pC- and pU-treated cell lysates showed increased expression of
p27
Kip1. The pCU-treated cells showed a further increase in
p27
Kip1 expression in both the cell lines. Untreated control and
SV-treated cells showed very low expression of p27
Kip1 (Fig. 2A
&B). The p27
Kip1 protein is generally phosphorylated at Ser10 and
Thr187 positions and its activity depends on its phosphorylation
status. Therefore, we checked the phosphorylation status of
p27
Kip1 by immunoblot analysis and found that the treatments
reduced the phosphorylation of p27
Kip1 at Ser10 and Thr187 in
both the cells lines compared to the controls. Immunoflourescence
staining assay revealed that the treatments induced an increase in
p27
Kip1 localization in the nucleus when compared with control
cells (Fig. 2C) and a higher number of cells expressing p27
Kip1 in
the nuclei was observed with the pCU treatment (Fig. S2A). These
results were further confirmed by immunoblot analysis for p27
Kip1
protein in cytosolic and nuclear fractions (Fig. S2B).
To further confirm the role of p27
Kip1 in growth arrest induced by
the depletion of cathepsin B and uPAR, we knocked down the
expression of p27
Kip1 alone or in combination with uPAR and/or
cathepsin B, and we analyzed cell proliferation using BrdU
incorporation assay. As expected, immunoblot analysis showed
efficient knockdown of p27
Kip1 in p27
Kip1 siRNA-treated cells lysates
(Fig. 2D). Cell proliferation was also increased (11862%) with the
p27
Kip1 siRNA treatment in SNB19 and U251 cells as compared to
controls (97–100%) (Fig. 2E). In contrast, immunoblot analysis and
BrdU incorporation assay of cells from p27
Kip1 and cathepsin B or
uPAR co-depleted cells showed a decrease in p27
Kip1 expression but
the inhibitory effect induced in proliferation by pU, pC and pCU
treatments (as described in Fig. 1C) was reverted partially in co-
depleted cells (pU+p27si: 8262%, 7962%, pC+p27si: 7961%,
7762% pCU+p27si: 6662%, 6463% in SNB19 and U251 cells,
Mechanism of G0/G1 Arrest
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other molecules of G1 phase might be needed for complete growth
arrest. When FACS analysis was performed, p27
Kip1 knockdown and
the co-depletion treatments resulted in a decrease of cells in the G0/
G1 phase and a concomitant increase in cells in S and G2/M phases
(Fig. S2C).
G0/G1 phase regulators
Cell cycle regulators at the G0/G1 and G1/S phase transition
were analyzed after the above mentioned treatments. As p27
Kip1 is
both an inhibitor and a substrate of cyclin E-Cdk2 complex [25],
we analyzed the expression of these molecules using immunoblot
analysis and found that the treatments decreased the expression of
cyclin E whereas the expression of Cdk2 was unaffected (Fig. 3A).
Similarly, expression of aV, b3, aVb3 integrins decreased with the
treatments. Further, Cdk2 was immunoprecipitated from the cell
lysates of untreated and SV, pU, pC and pCU treated SNB19 and
U251 cells and immunoblotted for cyclin E. The results revealed
little or no expression of cyclin E in pU, pC and pCU treated cell
lysates compared to control and SV transfected cells indicating
that the treatments reduced the cyclinE-Cdk2 complex formation.
pCU-treated cells showed significant downregulation of cyclin E as
compared to pU and pC treatments. Dimerization of aVb3
integrin was checked by immunoprecipitating the cell lysate with
b3 integrin and immunoblotted for aV integrin and found that the
treatments significantly reduced the dimer formation. It was
further confirmed by native gel electrophoresis by using the aVb3
antibody (Fig. 3B).
Apart from the cyclinE-Cdk2 complex formation, the treat-
ments also decreased the expression of cyclin D1, p21, cyclin D2
and Ki67, which is an indicator of cell proliferation (Fig. 3A). We
also checked for the expression of Rb and p-Rb (Ser780 and
Ser249/Thr252) as p-Rb is initially catalyzed by the complexes
formed by cyclin D and Cdk4 or Cdk6 and later by cyclin E-Cdk2
[26,27]. We found that the treatments decreased the phosphor-
ylation status of Rb but did not affect total Rb (Fig. 3A).
Figure 1. RNAi-mediated depletion of cathepsin B and uPAR inhibits SNB19 and U251 cell proliferation and induces G0/G1 arrest.
A. Western Blot analysis of cathepsin B and uPAR in SNB19 and U251 cells 36 hrs after transfection with SV, pU, pC and pCU. GAPDH was used as a
loading control. Side panel shows quantitative analysis of cathepsin B and uPAR bands by densitometry. B. We analyzed cell proliferation 36 hrs after
transfection using the BrdU incorporation assay and the percent of proliferation is represented graphically. Values are mean 6 standard deviation
(SD) from three different experiments (p,0.01). C. Propidium iodide-stained SNB19 and U251 cells were analyzed for DNA content using flow
cytometry. The graph shows the percentage of cells in G0/G1, S and G2/M phases 36 hrs post transfection. Values are mean 6 SD of three different
experiments (*p,0.01, in comparison with the control).
doi:10.1371/journal.pone.0011668.g001
Mechanism of G0/G1 Arrest
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Kip1 is influenced by the upregulation of
FOXO3a proteins in cathepsin B and uPAR depleted cells
Since we observed p27
Kip1 upregulation with decreased cell
proliferation and G0/G1 phase arrest with the depletion of
cathepsin B and uPAR, we next determined the expression of
FOXO proteins, which are important transcriptional regulators of
the p27
Kip1 promoter. We also checked for the expression of PI3K
and AKT molecules, which dictate the phosphorylation status of
p27
Kip1 and affect the activity of FOXO proteins. Immunoblot
analysis revealed that the expression of FOXO3a increased with
the treatments, especially with pCU treatment (Fig. 4A); the
treatments did not affect the other FOXO forms significantly (Fig.
S3A).
For FOXO proteins to be active, newly synthesized FOXO3a
must translocate to the nucleus, which is further influenced by its
phosphorylation status. To test whether the depletion of uPAR
and/or cathepsin B affected localization of the FOXO3a protein,
cytosolic and nuclear fractions were immunoblotted for FOXO3a.
We found that the nuclear fractions of treated cells expressed more
FOXO3a protein than the controls (Fig. S2B). Further, immuno-
blot analysis of total cell lysates for phospho-FOXO3a revealed
that phospho-FOXO3a at Ser318 was decreased significantly
more than at Ser253. As expected, the same treatments decreased
the expression of phospho-PI3K and phospho-AKT; the total
forms were unaffected. The effect of the treatments was the same
in SNB19 and U251 cells.
PI3K is a known inhibitor of FOXO proteins. Hence, we
checked the effect of the PI3K inhibitor, LY294002 (10 mM) on
the expression of p-AKT in the total extracts. Western blotting
revealed decreased expression of p-AKT, which is an indicator of
PI3K kinase activity, and increased expression of FOXO3a and
p27
Kip1 in the nuclear extracts (Fig. 4B). FACS analysis showed
that the inhibitor induced G0/G1 arrest similar to that induced by
the RNAi treatments (Fig. 4C). The expression of p27
Kip1 and
Figure 2. Depletion of cathepsin B and uPAR increases p27
Kip1 nuclear localization. A. Expression of p27
Kip1 and p-p27 (Ser10 and Thr187)
were studied using immunoblot analysis. GAPDH was used as loading control. B. Total RNA isolated from untreated and treated SNB19 and U251
cells was subjected to semi-quantitative RT-PCR analysis using p27
Kip1 primers. Data represents average of triplicates normalized to GAPDH
(**p,0.01). C. 36 hrs after transfection with SV, pU, pC and pCU, cells were fixed, immunostained with anti-p27 antibody followed by Texas Red-
conjugated anti-mouse secondary antibody. DAPI was used for nuclear staining. Representative images of three independent experiments are shown.
D. SNB19 and U251 cells were transfected with siRNA against p27 (p27si) individually and in combination with pU, pC and pCU. The cells were also
transfected with control siRNA (C-si) and SV. Thirty six hours post-transfection, cells were lysed and the total lysates were immunoblotted for p27
Kip1,
p-p27 (Ser10), and p-p27 (Thr187). E. Effect of the above stated treatments on proliferation was assessed using BrdU incorporation assay. The graph
represents the percent of proliferating cells and the data represented are the average of three separate experiments (*p,0.05, **p,0.01, in
comparison with the control).
doi:10.1371/journal.pone.0011668.g002
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overexpressing cells, and we found a correlation with the above
mentioned results (Fig. S3B). These results indicate that the
knockdown of cathespin B and uPAR in SNB19 and U251 cells
induced G0/G1 arrest with the increased expression of p27
Kip1
and FOXO3a and reduced PI3K activity.
We further analyzed the effect of upregulation of FOXO3a on
p27
Kip1 expression at the transcriptional level. After transfecting
SNB19 and U251 cells with pU,pC and pCU or after treatment with
Ly294002 (10 mM), a second transfection was performed with the
cDNA constructs containing the luciferase reporter gene controlled
by FOXO binding promoter regions of human p27
Kip1 [23125 to
2845 bp (pGL-Kip1-290) and 23507 to 22478 bp (pGL-Kip1-
1110)] or the consensus sequence arranged as tandem repeats in
triplet (pGL-Kip1-3x) or mutated sequence (pGL-Kip1-M) or with
t h eS Va sac o n t r o l .T h ep 2 7
Kip1 promoter with the normal and
mutant versions of the putative FOXO binding sequence and the
regions used for PCR amplification are represented in Figure 5A.
Expression of luciferase was increased by 2–2.5 and 3 fold in pC- and
pU-transfected cells and LY294002-treated cells, respectively when
pGL-Kip1-290 (Fig. 5B), pGL-Kip1-1110 (Fig. 5C) and pGL-Kip1-
3x (Fig. 5D) vectors were used. In contrast, in pCU-transfected cells,
the same treatment increased luciferase expression by 4–4.5 fold.
Thus, increased activity of the p27 promoter expressed as luciferase
expression with the promoter constructs indicate that the regulation
of p27
Kip1 protein levels by cathepsin B and uPAR could be, at least
partially, explained by the regulation of its promoter activity by
increased expression of FOXO3a. The levels of luciferase expression
were same with all the constructs used whereas no expression was
observed either in mutated sequence driven luciferase construct
(Fig. 5E) or in the SV transfected controls.
Cathepsin B and uPAR shRNA suppresses intracranial
tumor growth
The effect of RNAi-mediated inhibition of cathepsin B and
uPAR on pre-established tumors was studied. H&E staining
revealed a large spread of tumor growth in mock and SV-treated
brain sections. Whereas, pre-established intracranial tumor growth
was inhibited by 95% when treated with pCU (Fig. 6A).
Immunohistochemical analysis of the tumor sections from control
mice for cathepsin B and uPAR showed increased expression
levels localized to the tumor region while the pCU-treated tumor
sections revealed very little or no expression of the cathepsin B and
uPAR. When probed for the expression of p27
Kip1 and Ki67
proteins, mock and SV-treated brain sections showed very little
Figure 3. Cathepsin B and uPAR knockdown decreases Cdk2 activity and the expression of aVb3 integrin. A. Cell lysates were collected
from SNB19 and U251 after transfection with SV, pU, pC or pCU. Western blot analysis of 50 mg of total cell lysates was performed to check the
expression of cyclin D1, cyclin D2, Cdk2, cyclin E, Rb, p-Rb, p21, aV, b3, aVb3 and Ki67. GAPDH was used as a loading control. B. Total lysates from the
untreated control and SV, pU, pC or pCU-transfected cells were immunoprecipitated for Cdk2 and b3 individually and then immunoblotted for cyclin
E and aV, respectively. The figure also shows the expression of aVb3 integrin on native gel.
doi:10.1371/journal.pone.0011668.g003
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Kip1 and increased expression of Ki67. In
contrast, pCU treated brain sections showed high expression of
p27
Kip1. However, pCU-treated brain sections showed very little
or no expression of Ki67 as compared to the controls (Fig. 6B),
indicating that cell proliferation is inhibited by these treatments
through upregulation of p27
Kip1. The effect of the pCU treatment
on tumors induced by SNB19 and U251 cells was the same.
Discussion
Various reports have demonstrated that cathepsin B and uPAR
levels are overexpressed during glioma progression [28–30]. It has
been reported that b1 integrins in caveolae bind uPAR and are
linked to increased secretion of pro-cathepsin B [31]. An
association of cathepsin B and uPAR mediated by active K-RAS
in colorectal carcinoma has also been reported [32]. We have
previously shown that RNAi-mediated downregulation of cathep-
sin B and uPAR led to decreased invasion, induction of
angiogenesis, increased caspase-mediated apoptosis, and induction
of G0/G1 arrest [2,30,33–37] Data from other reports indicate
that inhibition or depletion of cathepsin B prevents cells from
entering and leaving the cell cycle, thereby decreasing cell
proliferation [38,39]. However, the molecular mechanisms by
which cathepsin B and uPAR regulate cellular proliferation
remain poorly understood. The growing body of knowledge of
genetic alterations that occur in malignant gliomas has resulted in
the development of targeted therapy to restore cell cycle or
apoptosis defects in gliomas [22]. In the present study, we show
that the co-depletion of cathepsin B and uPAR arrests cells in the
G1 phase primarily through the upregulation of p27
Kip1 and that
this pathway involves the downregulation of p-PI3K, p-AKT, D-
type cyclin expression, and cyclin E/Cdk2 complex formation as
well as the subsequent upregulation of the FOXO3a protein and
its nuclear localization.
In the present study, we have shown that pU, pC and pCU
treatments reduced endogenous levels of cathepsin B and uPAR
proteins in SNB19 and U251 glioma cells (Fig. 1A) with a 75–78%
transformation efficiency as obtained using GFP (Fig. S4). Among
the treatments, pCU reduced protein expression more than pU
and pC; this same effect was seen in the other experiments. These
treatments also led to G1 arrest and decreased cell proliferation.
We further investigated the influence of these treatments on
p27
Kip1 expression and localization. Western blot analysis revealed
that p27
Kip1 expression increased with the treatments while its
Figure 4. Cathepsin B and uPAR knockdown induces FOXO3a expression and translocation to the nucleus by inhibiting PI3K
activity. A. After transfection, cell lysates were collected from the untreated control and SV, pU, pC or pCU-treated cells. Equal volume of total
protein was blotted for the expression of PI3K, p-PI3K, AKT, p-AKT, FOXO3a, p-FOXO3a (253), and p-FOXO3a (Ser 318). B. SNB19 and U251 cells were
treated with either DMSO or LY294002 (Ly 10 mM) for 24 hrs as mentioned in the Materials and Methods. After incubation, the total and nuclear
lysates were collected and probed for the expression of p-AKT, p27
Kip1 (Nu), FOXO3a (Nu) and lamin B (Nu). Equal loading was confirmed by the
GAPDH expression in the total cell lysate. C. After treatments with DMSO- and LY294002- cells were fixed, stained with propidium iodide and
subjected to FACS analysis to determine cell cycle status.
doi:10.1371/journal.pone.0011668.g004
Mechanism of G0/G1 Arrest
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indicating the nuclear localization of increased p27
Kip1 protein.
This was further confirmed by the immunofluorescence analysis
where the treatment showed nuclear presence of p27
Kip1. Data
from many different studies emphasize the importance of p27
Kip1
as a potent inhibitor of cell cycle in human cancers [40]. p27
Kip1
phosphorylation at Ser10 or Thr187 facilitates the nuclear-to-
cytoplasmic redistribution of p27
Kip1 [41,42], and this sub-cellular
localization determines the activity of p27
Kip1. Our results suggest
that reduced phosphorylation of p27
Kip1 at Ser10 and Thr187
increased p27
Kip1 nuclear localization, but further experiments
using p27
Kip1 siRNA and that of decreased expression of cyclin
D1, cyclin D2 and cyclin E with the pU, pC and pCU treatments
indicate that p27
Kip1 alone is partially responsible for cell cycle
arrest and decreased Cdk2 kinase activity might be necessary to
complete the task. Similar results showing that SHP1 downreg-
ulation effected p27
Kip1 expression and Cdk2-cyclin E complex
formation have been reported [43]. However, we were unable to
find any translocation difference of Cdk2 with the treatments as
observed by [43]. Our immunoprecipitation results indicate that
Cdk2 kinase activity was reduced with the treatments. As a
member of the CIP/KIP family, p27
Kip1 was found to be
associated with and to inhibit the catalytic activities of G1 and S
phase-specific Cdk/cyclin complexes [44]. Thus, the decrease in
p-p27
Kip1 with the treatments could be due to the low Cdk2 kinase
activity. Our results also indicate decreased phosphorylation of Rb
at Ser780 and Ser249/Thr252. Inactivated retinoblastoma (p-Rb)
protein regulates the progression from G1 to S phase through its
association with the E2F family of transcription factors [45,46]. In
early and late G1 phase, p-Rb is hyperphosphorylated by D-type
Cdks and Cdk2-cyclin E, respectively [26,47,48]. These reports
suggest conclusively that phosphorylation of p-Rb by Cdk2-cyclin
E requires p-Rb to be hypophosphorylated, and thus, the
inactivation of p-Rb involves sequential phosphorylation by cyclin
D-Cdk4/6 and cyclin E/Cdk2 [26,27]. Therefore, the G0/G1
arrest induced by the treatments could be due to the combined
action of reduced cyclin D1, cyclin D2, and cyclin E-Cdk2
complex formation and increased expression of p27
Kip1.
Hyperactivation of the PI3K-AKT pathway is critical in human
tumorigenesis because it promotes cell growth, survival and
resistance to treatment [49,50]. In addition, it has been reported
that 88% of gliomas show altered PI3K-AKT signaling [51].
Figure 5. Regulation of p27
Kip1 activity in cathepsin B and uPAR-depleted glioma cells occurs through FOXO3a transcription factor.
A. Schematic representation of the p27
Kip1 promoter with the normal and mutant versions of the putative FOXO binding site and the regions used
for PCR amplification. B–E. SNB19 and U251 cells were initially transfected with SV, pU, pC or pCU, and treated with Ly294002 (Ly 10 mM) separately.
24 hrs after the treatments, a second transfection with the luciferase constructs was performed as described in Materials and Methods. The luciferase
expression was quantified using Promega’s luciferase assay kit with a Turner Luminometer and is represented graphically. The graphs show luciferase
expression when pGL-Kip1-290 (B), pGL-Kip1-1110 (C), pGL-Kip1-3x (D), and pGL-Kip1-M luciferase constructs were used. Assessment for luciferase
expression was performed at least in triplicate (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0011668.g005
Mechanism of G0/G1 Arrest
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proliferation and survival [52]. In this study, we have shown that
downregulation of cathepsin B and uPAR significantly decreased
the dimer formation of aVb3 integrins as seen in immunoprecip-
itation and native gel electrophoresis with the decreased expression
of both aV and b3 integrins. The roles of other integrins are being
investigated in our laboratory. Transcriptional downregulation of
p27
kip1 mRNA by AKT occurs through localization and
subsequent inhibition of the FOXO protein. Recent data show
FOXO3a directly regulates p27
kip1 transcription [53,54], suggest-
ing that reduced p27
kip1 levels after a proliferative stimulus may
also be associated with FOXO3a. Our results further confirm
these findings. In the present study, FOXO3a expression was
positively correlated with p27
kip1 expression (Fig. 2A) but inversely
associated with cell proliferation as identified by Ki67 (Fig. 3A),
which is a marker of cell proliferation expressed specifically in the
cell nucleus from late G1 to S phase. We observed a decrease in
phosphorylation of PI3K, AKT and FOXO3a (Ser318) (Fig. 4A)
protein along with decreased activity of Cdk2 (Fig. 3B) with the
RNAi treatments. Activated AKT is crucial in preventing
FOXO3a displacement to the nucleus [55,56]. However, AKT-
independent and Cdk2-dependent phosphorylation affected
FOXO1 nuclear export to different extents in U87 and U251
glioma cells [22]. Our results reveal that LY294002 significantly
inhibited the phosphorylation and activation of AKT. More
importantly, LY294002-treatment caused FOXO3a nuclear
accumulation. These results suggest that LY294002 controlled
the activity of FOXO3a by regulating its phosphorylation and
subcellular localization. It is known that FOXO3a regulates the
transcription of p27
kip1 by binding to its promoter [57]. Indeed, we
found that p27
kip1 expression increased with LY294002 treatment.
Moreover, after treatment with pU, pC, pCU and Ly294002,
luciferase expression under the influence of FOXO binding
promoter region of p27
Kip1 increased with the treatments as
compared to control and SV-transfected cells. Among the
treatments, pCU-treated cells showed more luciferase activity
than pU- and pC-treated cells. Notably, luciferase expression was
nearly the same irrespective of the vector used. Studies have
indicated that other transcription factors, such as Sp1, CRE and
NF-kB, regulate p27
Kip1 promoter activity [58,59]. Very recently,
Li [60] reported the effect of anti-inflammatory drugs on
proliferation of human osteoblasts with the increased activity of
FOXO3a by binding to p27
Kip1 promoter. Thus, these findings
invite the conclusion that the increased p27
Kip1 expression with
Figure 6. In vivo inhibition of tumor growth. Stereotactic implantation of SNB19 and U251 (1610
5) tumor cells was performed and, after one
week, PBS (mock), SV or pCU was injected into the brain using an Alzet mini osmotic pump. Five animals per group were used. 30 days after
implantation, the animals were sacrificed, the brains were removed and fixed, and paraffin sections were prepared. A. Hematoxylin and eosin staining
of tissue sections to visualize tumor cells and to examine tumor volumes. Bar: 20 mM( * p,0.01) B. Immunohistochemical analysis of cathepsin B,
uPAR, Ki67 and p27
Kip1 in paraffin embedded tissue sections. Bar: 200 mM.
doi:10.1371/journal.pone.0011668.g006
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FOXO3a, which binds to the -2984 bp region on the p27
Kip1
promoter and could be mediated by the low expression of p-AKT.
The results obtained were also confirmed by immunoblotting for
p-PI3K, p-AKT, FOXO3a and p27
Kip1 in the cathepsin B and
uPAR-overexpressed SNB19 and U251 cells.
Although overexpression of p27
Kip1 can induce protection from
apoptosis, other studies have reported pro-apoptotic effects where
caspases are able to cleave p27
Kip1 in a cell type specific manner
[9,61] reported that the inhibition of cytochrome c release might
be a possible mechanism of preventing apoptosis with higher
p27
Kip1 expression in leukemia cells; this indicates that the
regulation of the apoptotic process by p27
Kip1 might vary with
cell transformation status. In a separate experiment, we observed
decreased expression of p27
Kip1 in the nucleus at the 72 hours
time point (data not shown). Several recent reports have shown
that p27
Kip1 has cell cycle-independent functions, such as the
regulation of cell migration, which might be oncogenic under
certain circumstances [25].
The efficiency of in vivo RNAi/adeno virus treatments by
targeting proteins like uPA and uPAR [62], cathepsin B and uPAR
[3], and uPAR and MMP-9 [63] has been well established in our
laboratory. Similarly, the present study demonstrates that the
simultaneous downregulation of cathepsin B and uPAR caused the
regression of intracranial tumors. Nude mice implanted intracra-
nially with SNB19 and U251 glioma cells became very weak
within three to four weeks due to tumor development. In contrast,
pCU-treated mice were healthy, and H&E staining of these tissue
sections revealed very few to no cancer cells as compared to the
controls. Interestingly, we observed high expression of p27
Kip1 and
very low expression of Ki67 in the tumor sections, indicating the
efficiency of treatment both in vitro and in vivo. Moreover, a direct
correlation between the low expression of p27
Kip1 and FOXO3a
and higher expression of Ki67 with the malignant glioma has been
reported [23]. Increased expression of p21 and regression of lung
tumor growth in vivo with the administration of decorin has been
reported [64]. Yu [65] has reported that the downregulation of
uPAR induced G0/G1 arrest in vitro but did not affect growth in
vivo. Decreased tumor growth and metastasis of malignant
melanoma cells in nude mice with the administration of antisense
oligonucleotide for uPAR has been described [66]. Likewise, an
88% inhibition of proliferating cancer cells in colorectal carcinoma
in vivo when treated with uPAR monoclonal antibody (ATN658)
has been reported recently [67]. In contrast, uPAR overexpression
inhibited cell growth in murine embryonic fibroblast cells and
induced cell growth in keratinocytes [68]. uPAR has been detected
as a potential cooperating oncogene in Ink4a KO mice, which are
deficient in cell growth control [69]. Thus, the effect of uPAR on
growth rate may depend on cell type. Not much has been reported
about cathepsin B controlling cell proliferation in vivo.I n
conclusion, our results demonstrate that Akt/FOXO3a/p27
Kip1
signaling contributes to G0/G1 arrest, which was induced by the
depletion of cathepsin B and uPAR (Fig. 7). Moreover, our results
also demonstrate that the bicistronic construct, pCU, was more
effective than the single constructs, pU and pC. Thus, our findings
provide molecular mechanism for the G0/G1 arrest induced by
the downregulation of cathepsin B and uPAR in SNB19 and U251
glioma cells.
Materials and Methods
Ethics Statement
The Institutional Animal Care and Use Committee of the
University Of Illinois College Of Medicine at Peoria, Peoria, IL,
USA approved all surgical interventions and post-operative animal
care. The consent was written and approved. The approved
protocol number is 851, dated November 20, 2009. No de novo
cell lines were used.
siRNA constructs, cell culture, transfection and inhibitor
treatments
Single shRNA constructs directed against uPAR (pU) and
cathepsin B (pC) and the bicistronic construct directed against
both cathepsin B and uPAR (pCU) have been described previously
[2]. siRNA for p27
Kip1 (p27si) was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Full length cathepsin B and
uPAR over expressing plasmids were purchased from Origene
(Rockville, MD). All the antibodies used in this study are from
Santa Cruz Biotechnology (Santa Cruz, CA) unless otherwise
mentioned.
Human glioma cell lines SNB19 and U251, obtained form
American Type Culture Collection (ATCC, Manassas, VA) were
cultured in DMEM/high glucose media supplemented with 10%
FBS in a humidified atmosphere containing 5% CO2 at 37uC.
Cells were grown in 100 mm dishes for all treatment conditions
and on two-well chamber slides for immunocytochemistry
analysis. Scrambled vector (SV- sequence corresponds to the
bicistronic shRNA directed against the cathepisn B and uPAR),
pU, pC and pCU vectors were transfected into SNB19 and U251
cells independently with Fugene 2000 reagent as per the
manufacturer’s instructions (Roche, Indianapolis, IN). For the
inhibitor study, cells seeded in six well plate were treated with
Ly294002 (10 mM), a potent PI3K inhibitor, for 24 hrs.
Figure 7. Schematic representation of the molecular mecha-
nisms proposed in the regulation of cell proliferation by G0/G1
arrest with the increased expression of FOXO3a and p27
Kip1 in
cathepsin B and uPAR-depleted glioma cells.
doi:10.1371/journal.pone.0011668.g007
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Cell proliferation analysis was performed using Cell Prolifera-
tion ELISA (colorimetric) BrdU incorporation assay (Roche
diagnostics, Indianapolis, IN), according to the manufacturer’s
protocol. Cell viability analysis was performed by MTT assay
using the Cell Titer 96 colorimetric assay as described previously
[3]. Phases of cell cycle were analyzed using flow cytometry after
36 hrs and 48 hrs of transfection. Cells were trypsinized, washed
with 1X PBS, fixed and permeabilized with cold 70% ethanol and
finally incubated for 30 min with 1 mL of propidium iodide
(conatins NP-40) (Biosure, CA) in the dark. The DNA content of
these cells was measured based on the presence of propidium
iodide (PI)-stained cells. Flow cytometric analysis was done on at
least 10,000 cells from each sample, and cell cycle data were
analyzed using a FACS Calibur flow cytometer (BD BioSciences,
San Jose, CA) with an excitation wavelength of 488 nm and
emission wavelength of 530 nm.
RT-PCR, Western blot and immunoprecipitation analysis
36 hrs after transfection, total RNA was isolated using Trizol
reagent (Invitrogen, Carlsbad, USA) and converted to cDNA using
Transcriptor First Strand cDNA synthesis kit (Roche diagnostics,
Indianapolis, IN) as per manufacturer’s instructions. PCR was
performed for p27 mRNA expression using forward 59TCAAAG-
CAAGCTCTTCATACCC39 and reverse 59GCACATAAAC-
TTTGGGGAAGG39 primers. For immunoblot analysis, cells
were washed with ice-cold DPBS and resuspended in 150 mLo f
radioimmune precipitation assay buffer. The cell lysates were
analyzed by SDS-PAGE followed by western blotting. The
following antibodies were used: uPAR, cathepsin B, (Athens
Research and Technology, Athens, GA, USA) aV (Millipore,
Billerica, MA), b3, aVb3, PI3K, p-PI3K, AKT, p-AKT (Cell
Signaling, Boston, MA), p21, p27
Kip1, p-p27
Kip1 (Ser10), p-
p27
Kip1 (Thr187), cyclin D1, cyclin D2, Cdk2, cyclin E, Ki67,
FOXO3a, p-FOXO3a (Ser253), FOXO3a (Ser318/321),
FOXO1, p-FOXO1 (Ser256) (Cell Signaling, Boston, MA), Rb,
p-Rb (Ser780 and Ser249/Thr252) and GAPDH. Signals were
detected using Pierce Western Blotting substrate (Pierce, Rockford,
IL), and the chemiluminescent images were captured in the
Flourchem Q, Alpha Innotech, Gel Documentation system. Also,
a native gel electrophoresis (7%) was performed on PAGE in the
absence of SDS without denaturing the proteins to check the
dimerization of aVb3 integrin
b3 and Cdk2 was immunoprecipitated from 300 mg of total
protein using anti- b3 and -Cdk2 antibody and protein A plus G
agarose beads (20 mg). The precipitates were washed five times
with lysis buffer and once with PBS. The pellet was then
resuspended in sample buffer (50 mM Tris, (pH 6.8), 100 mM
bromophenol blue, and 10% glycerol) and incubated at 90uC for
10 min before electrophoresis to release the proteins from the
beads and immunoblotted for aV and cyclin E, respectively.
Isolation of nuclear and cytoplasmic cell fractions
Cytoplasmic and nuclear extracts from the treated cells were
isolated using Active Motif nuclear extraction kit (Active Motif,
Carlsbad, CA) according to the manufacturer’s instructions.
Harvested cells were washed once with 1X PBS, the cell pellet
was resuspended in 200 mL of hypotonic buffer, incubated for
30 min at 4uC on a rocking platform, and centrifuged. The
supernatant was collected as the cytosolic fraction. The nuclear
pellet was resuspended, homogenized and incubated in complete
lysis buffer provided in the kit for 30 min at 4uC on a rocking
platform, and the nuclear fraction was collected after centrifuga-
tion. Immunoblot analysis was performed with the cytoplasmic
and nuclear fractions for proteins like p27
Kip1 and FOXO3a.
Nuclear fractions were also tested for the expression of the
lamin B.
Immunofluorescence assay
Human glioma cells (SNB19 and U251) grown in two-well
chamber slides were treated as described earlier. The cells were
washed with PBS, fixed with 4% paraformaldehyde, permeabi-
lized with ice-cold methanol, and rehydrated with PBS. PBST
containing 2% BSA was used for blocking the cells for one hour
followed by a two-hour incubation with anti-p27
Kip1 antibody
(Cell Signaling, Boston, MA) at a dilution of 1:300 in PBST
containing 2% bovine serum albumin, followed by a final
incubation with Texas Red conjugated secondary antibody
(1:1000 in PBS/2% bovine serum albumin, 0.5% tween 20) for
one hour. Expression was visualized by fluorescence microscopy
((Olympus IX71; Olympus Optical Co, Tokyo, Japan)) and
photographed.
Construction of human p27
Kip1 promoter reporter vector
and luciferase activity
To determine the FOXO influenced promoter activity of
p27
Kip1, three tandem repeats of FOXO binding consensus
sequence (GACTGTAAACAAAAC) comprising a 59 end phos-
pho modification and SacI and XhoI restriction sites on 59and
39ends of upper and bottom strands, respectively, were cloned into
the pGL3 basic vector and labeled as pGL-Kip-13x. The
consensus sequence is positioned at 22984 to 22992 bp. Another
plasmid was constructed by altering the consensus sequence
(TTGTTTACAA to TTGTGCGCTA) to serve as a negative
control and also to show the specificity of the consensus sequence
towards FOXO. Similarly, the human p27
Kip1 promoter was
amplified from genomic DNA using the following primers:
F- aaaGAGCTCCCCACTTTGCAGAAGGATG and
R-aaaCTCGAGGAGCACCATTTTGTCGCTTT;
F-aaaGAGCTCACCTTCGCAGAAACATTTGG and
R-aaaCTCGAGGCAAGAGGTCTCATCCTCTTTA with
SacI and XhoI restriction sites on 59 and 39 regions of forward
and reverse primers, respectively. These primers amplify a 290 bp
(located between 23125 to 2845 bp) and an 1110 bp (located
between 23507 to 22478 bp) region that includes the FOXO
binding consensus sequence. The PCR product was cloned into
the promoter-less luciferase reporter vector, pGL3 basic (Pro-
mega), predigested with SacI and XhoI, and labeled as pGL-Kip1-
290 and pGL-Kip1-1110, respectively.
Luciferase activity was measured with Promega’s luciferase
assay kit. Following 24 and 48 hrs of transfection, cells were
washed twice with PBS and lysed with 100 mL of reporter lysis
buffer. The lysate was shaken at room temperature for
10615 min, after which 20 mL of each cell lysate was mixed with
100 mL of buffer and measured for luciferase activity in a Turner
Luminometer (Turner Designs, Sunnyvale, CA, USA) over an
integration period of 15 sec. Values obtained were normalized to
GAPDH levels.
Intracranial glioma cell implantation, treatment and
immunohistochemistry
Stereotactic implantation of SNB19 and U251 glioma cells
(1610
5), followed by treatments with mock, SV and pCU using
Alzet minipumps at the rate of 0.25 mL/hr, the eventual sacrifice
of glioma-bearing mice, and tumor processing were carried out as
previously described [62,70]. Sections were stained with hema-
toxylin and eosin (H&E) to visualize tumor cells and to examine
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evaluated by a neuropathologist who was blinded as to the
treatment group and scored semiquantitatively for tumor size, as
described previously [3,71]. Five animals were used per treatment.
The average tumor area per section integrated to the number of
sections where the tumor was visible was used to calculate tumor
volume and compared between controls and treated groups.
Immunohistochemistry for p27
Kip1, cathepsin B, uPAR and Ki67
was performed as described earlier.
Statistical analysis
Values are shown as means 6 SD of at least three independent
experiments. Results were analysed using a two-tailed Student’s t-
test to assess statistical significance. p,0.05 was considered
significant.
Supporting Information
Figure S1 RNAi-mediated depletion of cathepsin B and uPAR
affects cell viability and proliferation in SNB19 and U251. A. We
analyzed cell viability 36 hrs after transfection using the MTT
assay, and the percent of viable cells are represented graphically.
Values are mean 6 standard deviation (SD) from three different
experiments (p,0.01). B. After 48 hrs of transfection with SV, pC,
pU and pCU, cells were collected, stained with propidium iodide
and analysed for DNA content using flow cytometry. The graph
shows the percentage of cells in sub G0/G1, G0/G1, S and G2/M
phases. Values are mean 6 SD of three different experiments
(*p,0.01).
Found at: doi:10.1371/journal.pone.0011668.s001 (0.14 MB TIF)
Figure S2 Cathepsin B and uPAR knockdown induces p27
Kip1
and FOXO3a nuclear translocation. A. The ratio of nuclear vs
cytoplasmic distribution of p27
Kip1 in SNB19 and U251 cells after
immunocyto analysis for p27
Kip1 were calculated and represented
graphically. The values are an average calculated from ten
different fields (*p,0.01). B. After transfection with SV, pU, pC
and pCU, SNB19 and U251 cells were collected, and proteins
from the cytosolic and nuclear fractions were isolated. Immuno-
blot analysis was performed for the expression of p27
Kip1 and
FOXO3a in nuclear fractions. The RNAi treatments increased the
expression of the above mentioned molecules. C. Glioma cells
were treated with siRNA for p27
Kip1 individually and in
combination with SV, pU, pC and pCU. The cells were subjected
to FACS analysis. The graph shows the percent of cells distributed
in G0/G1, S and G2/M phases of cell cycle. Values are mean 6
standard deviation (SD) from three different experiments
(*p,0.01).
Found at: doi:10.1371/journal.pone.0011668.s002 (5.63 MB TIF)
Figure S3 FOXO1 expression is unaffected by treatment with
pU, pC and pCU; p27
Kip1 and FOXO3a expression decreases
with the upregulation of cathepsin B and uPAR. A. Immunoblot
analysis of total protein isolated from transfected SNB19 and
U251 cells. Immunoblot analysis was performed for the expression
of FOXO1, p-FOXO1 (Thr24), p-FOXO1 (Ser256), p-FOXO1
(Ser319)/FOXO4 (Ser262), p-FOXO4 (Ser262) and GAPDH. B.
SNB19 and U251 cells were transfected either with SV or full
length uPAR (fl-U) or full length cathepsin B (fl-C). Total cell
lysates were collected and immunobloted for the expression of
uPAR, cathepsin B, p-PI3K, p-AKT, p27
Kip1, FOXO3a and
GAPDH.
Found at: doi:10.1371/journal.pone.0011668.s003 (0.62 MB TIF)
Figure S4 Transfection efficiency in glioma cells. Glioma cells
were transfected with GFP using Fugene (1:3, Fugene: plasmid
ratio). Shown are the images, after transfections,taken under bright
and fluorescent fields.
Found at: doi:10.1371/journal.pone.0011668.s004 (0.46 MB TIF)
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